Ex-Gilead Irish operations leader joins Alexion to expand in Dublin, Athlone

Chutes and Ladders

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email | Twitter) and we will feature it here at the end of each week.

Ex-Gilead Irish operations leader joins Alexion to expand in Dublin, Athlone

Former vice president of operations and general manager for Ireland at Gilead Sciences ($GILD) Julie O'Neill joined Alexion Pharma's ($ALXN) Ireland site to be the general manager and senior vice president of global manufacturing operations there. At Gilead, O'Neill was also in charge of Irish expansion. Alexion's move into the country created about 90 new jobs at two sites, one in Athlone and another in Dublin. Article

Alexion
Julie O'Neill is the new general manager and vice president of global manufacturing operations at Alexion Pharma Ireland.


Sucampo
Peter Greenleaf joined Sucampo as its CEO.


Biotech

Sucampo Pharmaceuticals ($SCMP) appointed Peter Greenleaf as the company's CEO. Release

> Jeffrey Hessekiel has been named executive vice president and general counsel of Exelixis ($EXEL). Release

> Seattle Genetics ($SGEN) appointed Chris Boerner as executive vice president of its commercial side and Charles Romp as senior vice president of sales. Release

Keryx Biopharmaceuticals ($KERX) brought on Greg Madison as its chief operating officer. Release

> MYOS has appointed Dr. Robert Ashton as chief medical officer. Release

> Alliqua ($ALQA) appointed Dr. Janice Smiell as its first chief medical officer. Release

> Carl Adams joined NeuroSigma as the company's vice president and controller. Adams was a finance executive at Amgen ($AMGN) prior to NeuroSigma. Release

The Biocom Institute appointed Liisa Bozinovic as executive director beginning Mar. 3. Release

> Spark Therapeutics appointed industry leader Elliott Sigal to its board of directors. Sigal was formerly executive vice president and chief scientific officer at Bristol-Myers Squibb ($BMY). Release

> Arvinas hired Jim Winkler as the company's chief scientific officer. Release

> Osiris Therapeutics ($OSIR) brought on Frank Czworka as its vice president and general manager of wound care. Release

> USDM Life Sciences appointed Brian McCole as director of its enterprise quality management practice. Release

> Parcell Laboratories has promoted Colin White to the newly created position of chief scientific officer. Release

> Dr. Seymour Fein has been appointed chief medical officer at Ventria Bioscience. Release

> Brian O'Callaghan has been appointed as Sonrgy's chairman and CEO. David Renas is also joining Sonrgy as CFO. Release

> Regulus Therapeutics ($RGLS) has appointed Martin Beaulieu the head of Regulus microMarkers, an R&D division of Regulus. Release

Genelux has appointed John Prunty as chief financial officer. Release

Pharma

> Merck Serono has named Dr. John Orloff as head of global clinical development. Release

> SciClone Pharmaceuticals ($SCLN) appointed Charles Meng as general counsel and vice president of compliance. Release

Joseph DePinto joined Sunesis Pharmaceuticals ($SNSS) as the company's executive vice president and chief commercial officer. Release

> Tokai Pharmaceuticals has appointed John McBride as chief operating officer. Release

> Lynnette Dillen has joined Innovus Pharma as executive vice president and chief financial officer. Release

> Zocere has named Kenton Zavitz as its chief scientific officer. Release

CRO

> INC Research hired Beatrice Setnik as its VP of clinical pharmacology. More

Medical Devices

> Emperra has appointed Christian Krey as managing director and CEO. Release

> Miramar Labs brought on R. Michael Kleine as its new president and CEO. Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.